NCT06213285

Brief Summary

The APPEND-CT registry is an investigator-driven multicenter retrospective observational database intended to compile cardiac CT follow-up data after Watchman FLX device implantation and function as a platform for answering clinical and research questions within LAAC follow-up. The derived studies should support therapeutic decision-making, improve risk-stratification in LAAC and help generate hypotheses for potential future clinical intervention trials.

Trial Health

58
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2024

Shorter than P25 for all trials

Geographic Reach
2 countries

2 active sites

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 9, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 19, 2024

Completed
26 days until next milestone

Study Start

First participant enrolled

February 14, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2024

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2025

Completed
Last Updated

May 30, 2024

Status Verified

May 1, 2024

Enrollment Period

6 months

First QC Date

January 9, 2024

Last Update Submit

May 29, 2024

Conditions

Keywords

Left Atrial Appendage OcclusionCardiac Computed TomographyWatchman FLX

Outcome Measures

Primary Outcomes (1)

  • Ischemic stroke

    Clinically affirmed ischemic stroke

    Minimum 12 months

Secondary Outcomes (3)

  • Device-related thrombosis

    Minimum 12 months

  • Major bleeding

    Minimum 12 months

  • All-cause and cardiovascular mortality

    Minimum 12 months

Interventions

Early (30-120 days) CT follow-up after Watchman FLX LAAO

Also known as: left atrial appendage closure, LAAO, LAAC

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Watchman FLX implanted patients with a minimum of one early follow-up cardiac CT.

You may qualify if:

  • Watchman FLX LAAO
  • A minimum of one follow-up cardiac CT performed within 30-120 days post-procedure.
  • A minimum of one year clinical follow-up data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Mayo Clinic

Rochester, Minnesota, 55901, United States

Location

Aarhus University Hospital

Aarhus, 8200, Denmark

Location

MeSH Terms

Conditions

Ischemic StrokeAtrial Fibrillation

Interventions

Left Atrial Appendage Closure

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesArrhythmias, CardiacHeart DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Cardiac CatheterizationCatheterizationTherapeuticsInvestigative Techniques

Study Officials

  • Anders Kramer, MD

    Aarhus University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD-fellow

Study Record Dates

First Submitted

January 9, 2024

First Posted

January 19, 2024

Study Start

February 14, 2024

Primary Completion

August 1, 2024

Study Completion

January 1, 2025

Last Updated

May 30, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Patient data will be registered under a pseudonymous registry-ID and will not be personally identifiable.

Locations